Amati AIM VCT plc
Annual Report & Financial Statements 2022
9
Information for Shareholders
Financial Statements
Reports from the Directors
Strategic Report
Highlights
grids, without requiring significant spend on
infrastructure or equipment. We invested £3m in
Flylogix in November. Flylogix has developed remotely
piloted small fixed-wing aircraft that can be used for
monitoring purposes in remote locations at sea. Its
initial focus is on the measurement of methane
emissions from oil and gas infrastructure in the North
Sea, but is expanding this service to other
geographies, led by customer demand. It is also
looking to enter the market for bird and mammal
surveys for prospective wind farms around the UK.
Remotely piloted aviation is safer, cheaper and has a
much reduced carbon footprint versus conventional
aviation. There are several demand drivers and
applications worldwide for its technology, which has
brought together smart software, 4G and satellite
communications, and low-cost electronics to develop a
new generation of smaller, more efficient aircraft.
IPO Investments
We supported three new healthcare IPOs. In May we
invested £1.9m in Arecor Therapeutics, a drug
development services company, which uses its Arestat
platform to enhance the formulation of drugs to
improve their therapeutic properties. Arecor has an
impressive list of pharma, generic and biotech clients
as well as potential significant upside from an
internally developed pipeline of clinical programmes
and has performed well since float. In the same month
we invested £0.7m in Trellus Health, whose software
platform provides expert personalised care for the
treatment of Inflammatory Bowel Disease and other
complex chronic conditions, aiming to cut healthcare
costs by reducing hospital admissions and tailoring
care to the individual patient to improve their resilience
in the face of their symptoms. In December we
invested £3.6m in Aptamer. The company develops
affinity ligands, which are biological molecules that
bind other molecules, in the way that antibodies do for
example. Aptamers are very small in comparison, and
their attributes offer benefits to cost, manufacturing
and likelihood of binding. The company works with
75% of the world’s top 20 pharma companies with
repeat custom. Clients use Aptamers across
healthcare applications, such as therapeutic delivery,
purification, diagnostics and bioprocessing.
Three of the eight IPO investments added to our
portfolio of software, training and ecommerce
companies. In May we invested £3m in Glantus, which
had developed software to automate the process of
checking and auditing Accounts Payable items for
large corporate customers. This is a function in the
past that has often been taken on by specialist
consultants. Glantus has acquired two such
consultancy businesses, allowing it to gain from the
efficiency that the software can bring, whilst
broadening its customer reach. This is a competitive
area, but one in which Glantus has a broad product
set and customer base, with low levels of churn. In
March we invested £1.7m in In the Style, an
ecommerce retailer specialising in providing inclusive
clothing collections by social media influencers. Sales
have grown strongly during the pandemic, but supply
chain issues brought margins down to hardly
breakeven. After some disappointments, a change of
management has seen the founder replaced as CEO,
bringing in a more experienced pair of hands. Lastly, in
July we invested £1.8m in Northcoders, which
provides training to IT novices and junior software
engineers. There continues to be an acute shortage of
coders, programmers, and developers in the UK.
Recently the company has expanded into providing
apprenticeship courses. Northcoders’ student numbers
and revenues took an inevitable hit in 2020 from the
impact of the pandemic, but the company reacted
quickly and within six months it was able to transition
its onsite offering into on-line courses. It can now offer
a full range of onsite and hybrid-online content from
its technology-based teaching platform. This
operational leverage will drive EBITDA margins to
more than 30%, and the IPO funds will enable the
company to expand to new locations.
The remaining two IPOs were in buildings related
products - and services which are coming to the fore
for environmental reasons; we invested £0.75m in
Zenova in July and £1.95m in Eneraqua in November.
Zenova has developed an intriguing array of new fire
safety, thermal insulation, and temperature
management technologies in the form of paints,
renders and sprays. The remarkable features of these
products can be seen in demo videos on the
company’s website. Due to the early stage of the
business, we made a small investment but with a right
to subscribe for a further 6,578,947 shares up to 9
months after the IPO. Eneraqua designs and installs
energy and water systems for large buildings in both
the public and private sectors, involving ground and air
source heat pumps. It has a patented device which
overcomes variable mains pressure to provide
constant water flow. This reduces water consumption
which in turn reduces heating requirements and